Primary lateral sclerosis: clinical, neurophysiological, and magnetic resonance findings


Abstract

Objective—To describe the clinical, neurophysiological, and MRI findings in 10 patients with primary lateral sclerosis (PLS).

Results—The course of the disease was very slowly progressive. Spasticity due to upper motor neuron dysfunction was the most prominent sign, but EMG showed slight lower motor neuron signs, such as a mixed pattern on maximal voluntary contraction and enlarged motor unit potentials. One patient had clinically mild lower motor neuron involvement. Central motor conduction times (CMCT) were more prolonged in PLS than is the case in ALS. Minor sensory signs were found on neurophysiological examination, comparable with those in ALS. In four patients serum creatine kinase activity was raised. On MRI cortical atrophy was seen, most pronounced in the precentral gyrus and expanding into the parietal-occipital region.

Conclusions—PLS is a distinct clinical syndrome, part of the range of motor neuron diseases. Besides pronounced upper motor neuron symptoms, mild lower motor neuron symptoms can also be found, as well as (subclinical) sensory symptoms. PLS can be distinguished from ALS by its slow clinical course, a severely prolonged MEP, and a more extensive focal cortical atrophy.

Keywords: primary lateral sclerosis; motor neuron disease

Primary lateral sclerosis (PLS) is a disorder characterised by spinobulbar spasticity due to upper motor neuron degeneration. It has been much debated entity in the past, because many reported patients seemed ultimately to have different diseases—for example, amytrophic lateral sclerosis (ALS), spinal multiple sclerosis, or cervical spondylotic myelopathy. Younger et al revived the syndrome on the basis of pathological observations and modern technical findings. In 1992 Pringle et al reported on a group of eight patients with PLS and established clinical and laboratory criteria. According to modern views, PLS is considered to be part of the range of motor neuron diseases consisting of primary lateral sclerosis, amytrophic lateral sclerosis (ALS), and progressive spinal muscular atrophy (PSMA).
The main finding in all patients was severe spasticity with accompanying corticospinal tract signs such as hyperreflexia, Babinski’s sign, pseudobulbar reflexes, and masseter hyperreflexia. The symptoms started in eight patients in the legs and were asymmetric in five patients. Spasticity was scored according to the modified Ashworth scale: grade 0 (no increase in tone), grade 1 (slight increase in tone, giving a “catch” when the affected part is moved), grade 2 (more pronounced increase in tone, but affected part easily flexed), grade 3 (considerable increase in tone; passive movement difficult), grade 4 (affected part rigid in flexion or extension).^{13} One patient had atrophy of the first interosseus, abductor digitii minimi, and abductor pollicis muscles in both hands, with normal strength and sensation and without fasciculations. The atrophy had developed very gradually over more than 8 years. An extensive search showed no cause for this abnormality. None of the other patients had clinical signs of lower motor neuron involvement.

Peripheral blood cell count was normal in all patients. Serum values for hepatic and renal function tests, calcium, and phosphate were normal. Creatine kinase was slightly increased in four out of nine patients. Immuneelectrophoresis was normal in nine patients and paraproteinaemia was absent. Anti-GM1 antibodies, hexosaminidase concentrations, very long chain fatty acid concentrations, vitamin B12 concentrations, and HTLV-1 antibodies were negative or normal in nine patients and not measured in patient 7. Normal serology or normal CSF in all patients excluded Lues and Borrelia infections. HIV serology was not performed because no patient had risk factors.

### Table 1 Clinical features

<table>
<thead>
<tr>
<th>Patient</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>V</td>
</tr>
<tr>
<td>Age of onset (y)</td>
<td>54</td>
<td>45</td>
<td>44</td>
<td>39</td>
<td>31</td>
<td>25</td>
<td>31</td>
<td>23</td>
<td>55</td>
<td>30</td>
</tr>
<tr>
<td>Family history</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Duration in years</td>
<td>6</td>
<td>8</td>
<td>18</td>
<td>7</td>
<td>35</td>
<td>10</td>
<td>6</td>
<td>11</td>
<td>8</td>
<td>18</td>
</tr>
<tr>
<td>First diagnosis</td>
<td>ALS</td>
<td>CM</td>
<td>LS</td>
<td>MS</td>
<td>ALS</td>
<td>LS</td>
<td>Park</td>
<td>MS</td>
<td>ALS</td>
<td>LS</td>
</tr>
<tr>
<td>Diagnostic delay (y)</td>
<td>5</td>
<td>2</td>
<td>3</td>
<td>6</td>
<td>28</td>
<td>0</td>
<td>2</td>
<td>10</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Weakness</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Site of onset</td>
<td>L leg</td>
<td>L leg</td>
<td>Legs</td>
<td>Legs</td>
<td>R arm</td>
<td>Legs</td>
<td>R leg</td>
<td>Legs</td>
<td>Speech</td>
<td>L leg</td>
</tr>
<tr>
<td>Spasticity/Ashworth</td>
<td>3</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>LMN signs</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sensory deficit</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pseudobulbar affect</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Urinary incontinence</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Barthel/Rankin scale</td>
<td>16/3</td>
<td>16/3</td>
<td>18/2</td>
<td>20/2</td>
<td>4/5</td>
<td>20/2</td>
<td>11/4</td>
<td>18/2</td>
<td>17/3</td>
<td>17/3</td>
</tr>
<tr>
<td>Medical aids</td>
<td>WCH</td>
<td>WCH</td>
<td>W</td>
<td>-</td>
<td>WCH</td>
<td>-</td>
<td>WCH</td>
<td>W</td>
<td>W</td>
<td>WCH</td>
</tr>
</tbody>
</table>

### Table 2 Laboratory findings

<table>
<thead>
<tr>
<th>Patient</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum chemistry</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
</tr>
<tr>
<td>Creatine kinase</td>
<td>62</td>
<td>25</td>
<td>20</td>
<td>24</td>
<td>66</td>
<td>22</td>
<td>24</td>
<td>90</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>Infectious serologies</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
</tr>
<tr>
<td>Immune-electrophoresis</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>NT</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
</tr>
<tr>
<td>Paraproteinaemia</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>NT</td>
<td>-</td>
<td>-</td>
<td>NT</td>
</tr>
<tr>
<td>Anti GM1 antibodies</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>NT</td>
<td>-</td>
<td>-</td>
<td>NT</td>
</tr>
<tr>
<td>CSF:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protein</td>
<td>0.39</td>
<td>0.67</td>
<td>0.48</td>
<td>0.40</td>
<td>0.32</td>
<td>0.53</td>
<td>0.77</td>
<td>0.42</td>
<td>0.74</td>
<td>0.43</td>
</tr>
<tr>
<td>OB/tgG index</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
</tr>
<tr>
<td>Cell count</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
</tr>
</tbody>
</table>

Norm=Normal; =absent; NT=not tested; OB=oligoclonal bands; CK normal=<0–50 u/l; CSF protein normal=<0.55 g/l.
for HIV. The CSF was normal with the exception of a slightly increased protein concentration in three patients (table 2).

The results of the motor nerve conduction velocity (MNCV), needle EMG, motor evoked potential (MEP), and somatosensory evoked potential (SSEP) examinations are presented in table 3.

Cranial MRI showed not only conspicuous precentral atrophy but also atrophy in the frontal and parietal-occipital regions (fig 1 and 2).

Cervical MRI or myelography was normal for all patients tested.

In the statistical analysis only a few significant results were found. Age of onset was significantly later for patients with pseudobulbar signs (Mann-Whitney p<0.01). In our series pseudobulbar signs were only present when the onset of the disease occurred at the age of 45 or later. No significant differences in chronological age or duration of the disease were found between these two subgroups. The absence of pseudobulbar signs was associated with the absence of urinary incontinence ($\chi^2=4.29, p<0.04$).
Discussion

The diagnosis PLS is made on clinical grounds. Commonly used criteria are adult onset, negative family history, gradual progression, spasticity with paresis of the legs for more than 3 years, and dysfunction clinically limited to the corticospinal tracts.3 Differential diagnosis of PLS includes many spinal cord syndromes. In all our patients the normal CSF or the absence of typical white matter densities on MRI ruled out chronic spinal MS. Infections such as HTLV-1, neuroborreliosis, or neurosyphilis were excluded by the normal serology or the normal CSF. Subacute combined degeneration of the cord due to vitamin B12 deficiency and metabolic diseases (adrenoleukodystrophy, hexosaminidase deficiency, cerbrotendinous xanthomatosis) were excluded in nine patients. Foramen magnum lesions or compression of the cord was excluded on clinical grounds and confirmed by cervical MRI or myelography in seven patients. Hereditary spastic paralysis was ruled out by a meticulous family history. PLS may be associated with malignancies but in our group these were absent.12

PLS usually is equally distributed between both sexes.2 In our series, however, there was a male preponderance. Median age of onset was 44.5 years. In all patients the clinical course was slowly progressive, from 6 to 35 years. There was no correlation between the duration of the disease and any of the clinical, laboratory, or EMG data. Three patients were diagnosed as PLS, but seven were at first misdiagnosed: three as ALS, two as multiple sclerosis, one as Parkinson's disease, and one as cervical compression myelopathy. It took between 2 and 28 years before the correct diagnosis was made. All patients had difficulties in walking, but only two patients had manifest weakness in the legs. In all cases the stiff, awkward, wooden way of walking was due to extreme spasticity. According to the Ashworth scale, seven patients were in grade 2, and two in grade 3. No correlation was found between the Ashworth scale and any of the other data. Five patients had bouts of unprovoked laughing and crying. This group with pseudobulbar signs differed significantly from the five others by their older age of onset. The patients without pseudobulbar signs had no urinary incontinence. One patient had clinical signs of lower motor neuron involvement—namely, an atrophy of the muscles of both hands, without weakness, fasciculations, or sensory loss. This atrophy had been present for more than 8 years and was very slowly progressive. No atrophy was present in other parts of the body. In the literature a few similar patients have been described.3 Three of our patients had urinary incontinence, probably due to bladder hyperreflexia.4 On detailed neuropsychological evaluation, mild cognitive impairment has been found in PLS, especially in frontal lobe function and memory.5 Our patients had no clinical signs of intellectual deterioration.

The Barthel index (BI) is a disability score; patients with a score of less than 17 are unable to live independently. The modified Rankin scale (MRS) measures handicap; a score of 2 or more means dependency. Our patients with a BI/MRS=20/2 could walk; the group of about 18/2 had a rollator, the others a wheelchair. Two patients were severely handicapped; these were the only ones with manifest loss of strength. Some patients had a remarkably good score even after many years of illness. This is by contrast with patients with ALS where the increase in dependency is measured in months.6

Serum creatine kinase may be increased in patients with ALS or PSMA, but no increase has ever been reported in patients with PLS.25 It was slightly increased in four of nine of our patients. An increased creatine kinase did not correlate with any of the clinical or EMG data. Protein concentrations in CSF are increased in 20%-30% of patients with ALS.20 22 Little is known about the CSF in patients with PLS, although an increased protein concentration has been mentioned.16 19 Three of our patients had an increased CSF protein.

Cortically evoked motor potentials are often absent in patients with PLS. When present, the central motor conduction time (CMCT) may be considerably prolonged, two to three times normal, by contrast with ALS where CMCT is normal or only slightly delayed.22-24 In three of our patients MEPs could not be elicited in the arms and legs, and in one only in the arms. Two patients had a normal CMCT to the arms (<2 SD); in the others CMCT was prolonged in arms and legs. In the legs this prolongation varied from 2.9 to 12.0 SD (mean 5.6 SD). The difference in CMCT between PLS and ALS is not easy to explain. Both disorders are due to the death of large pyramidal neurons in the cortex. In PLS the very protracted course (compared with ALS) may ultimately cause secondary demyelination of the pyramidal tracts, thus leading to a prolonging of the CMCT. We found considerable asymmetry for the CMCT in some patients; this has been mentioned before.4 The lower motor neuron remains spared in PLS, although occasionally slight signs of denervation in the EMG are found.1 22 None of our patients had acute denervation potentials but in four patients enlarged motor unit potentials (MUPs) and a mixed pattern on maximal voluntary contraction were present. These may be considered as signs of chronic denervation caused by slow lower motor neuron loss. There was no correlation between the presence of enlarged MUPs and the clinical or laboratory data of the patients.

Motor nerve conduction velocity in PLS is normal or prolonged.22 25 More than half of the patients in our group had slightly prolonged conduction velocities or values near the lower limit of normal in both upper and lower limbs. Slowing of MNCV has been found in patients with ALS where a preferential degeneration of the fast conducting myelinated axons in the peripheral nerve is presumed.26 The MNCV findings in our patients are comparable with those found in ALS.
Somatosensory evoked potentials in patients with PLS are reported to be normal or prolonged.1 27 28 We found at stimulation of the median nerve in three patients a prolonged central sensory conduction time (CSCT) (>2 SD). No responses could be obtained of the peroneal nerve in one patient. In the others CSCT was normal (two patients) or prolonged (from 2.5 to 10.4 SD, mean 5.4 SD). Despite this, the sensory system was clinically normal in all patients. In five patients the peripheral sensory system was tested. Sensory nerve response amplitude (SNRA) was diminished in one patient but normal in the others. Sensory nerve conduction velocity was near the lower limit of normal in all patients. On pathologica examination the sensory system is normal in PLS, especially in the posterior columns that are thought to convey the SSEP impulses.8 In patients with ALS a disturbed SSEP can also be found. Here a cortical origin has been suggested,9 as well as a combined involvement of peripheral and central pathways.10 Our findings in PLS match this second explanation.

In patients with PLS MRI shows atrophy of the frontoparietal part of the brain, most evident in the precentral area, with concomitant degeneration of the underlying white matter.6 10 This can be seen most clearly on images in the parasagittal plane. The mean surface area in this region may be reduced to 75% of normal.10 In early stages of the disease this is probably not as prominent as later on.9 These findings are by contrast with ALS where the size of the precentral gyrus is not different from controls, although shrinkage of the white matter is sometimes present.10 This difference in atrophy between PLS and ALS may be explained by the long duration of the disease in PLS. Brain MRI was carried out in nine of our patients. All showed atrophy of the frontal region, most prominent in the precentral gyrus (fig 1). We also saw atrophy in the parietal-occipital region of the brain (fig 2). Atrophy was most clearly depicted in the parasagittal images. Seven patients had a moderate enlargement of the ventricles. We considered this as secondary to the brain atrophy. In PLS as well as in ALS, increased signal intensities have been described at the site of the pyramidal tract on T2 weighted images.10 In only one patient did we see increased intensity in the posterior limb of the internal capsule extending into the corona radiata.

We conclude that upper motor neuron signs predominate clinically in patients with PLS, although, in rare cases, slight lower motor neuron symptoms may be present. On neurophysiological examination, however, lower motor neuron signs can be found more often.11 Primary lateral sclerosis has therefore to be considered as a part of the range of motor neuron diseases with predominant, but not exclusive, upper motor neuron involvement. We also found slight deficits in the sensory system, resembling those seen in ALS. Primary lateral sclerosis can be distinguished from ALS by the long duration of the disease, the extensive cortical atrophy and the considerable prolonging of the MEP. This distinction is important for the patient because a diagnosis of PLS does not have the same life threatening implications as ALS, at least not in the short term. The fewer lower motor neuron signs, the better the prognosis.

HISTORICAL NOTE

Emil Heinrich Du Bois-Reymond (1818–96)

This distinguished physiologist is remembered for two dissimilar contributions: he was a founder of electrophysiology of nerve and muscle; and he described his own migraine.

Du Bois-Reymond first discovered that the peripheral passage of a nerve impulse was accompanied by an electrical discharge,¹ the action potential. After Matteucci, whose work he disparaged, he is often regarded as the founder of electrophysiology.

Du Bois-Reymond was born and studied medicine in Berlin. His father was a watchmaker in the Swiss canton Neuchâtel but then moved to Berlin as a civil servant. Emil became a student of Johannes Müller, working with him from 1841 until Müller’s death in 1858. After years of industrious study, he succeeded him to the Chair of Physiology. At that time he was in close contact with Helmholtz, Brücke, and Ludwig, liaisons that culminated in the foundation of a new institute of physiology in Berlin in 1877. Du Bois-Reymond was the chief for 20 years.

He was described in somewhat antiquated terms, a materialistic, and a mechanical physiologist. Du Bois-Reymond invented a refined sensitive nerve galvanometer and a stimulus producing induction coil. He showed an electric current in muscle (Müskelstrom). It was, he thought, owing to an attempt to preserve a resting (pre-existing) difference of potential between the negative inner and positive outer membranes of the fibre, which caused an electromotive force appearing with injury—an important and new concept:

“The law of muscular current may be shortly expressed as follows: Any point of the natural or artificial longitudinal section of muscle is positive relation to any point of the natural or artificial transverse section, every particle of a muscle, however minute, ought to produce a current in the same manner as the whole muscle. As to the nerves they are possessed of an electromotive power, which acts according to the same law as muscles.”²

He confirmed Matteucci’s observation that during tetanus, the resting current flowing from an intact to an injured region is decreased and this negative variation was composed of a series of individual variations. This is called the negative variation (negative Schwankung) of Du Bois-Reymond. It now corresponds to variation in the action potential.

He investigated physiological tetanus³ in 1850 and employed in his work the galvanometer. By this means he defined what he called electroutomus, the potential changes produced by an externally applied current; he also experimented with Faradic stimulation. Du Bois-Reymond is also well known for his views on the pathogenesis of migraine.

Before his time, Robert Whytt had given an exposition of the spasm and relaxation of small blood vessels in migraine⁴ that fore-shadowed the vasospastic theories of Latham. Latham had initiated the vascular hypothesis and explained it as:

“a contraction of the blood vessels of the brain, and so diminished supply of blood, produced by the excited action of the sympathetic; and that the exhaustion of the sympathetics, following on this excitement causes the dilatation of the vessels and the headache.”⁵

This topic seems remote from the electrophysiological work of Du Bois-Reymond, but his account in 1860 displays a personal stake:

“a Tetanus takes place in the muscular coats of the vessels of the affected half of the head; in other words a Tetanus of the cerebral half of the sympathetic.”⁶ . . . every third or fourth weeks I am liable to an attack. I wake with a general feeling of disorder, and a slight pain in the region of the right temple, which, without overstep-ping the midline, reaches its greatest intensity at midday; towards evening it usually passes off. While at rest the pain is bearable, but it is increased by motion to a high degree of violence . . . It responds to each beat of the temporal artery. The latter feels on the affected side, like a hard cord, while the left is in normal condition. The countenance is pale and sunken, the right eye small and reddened . . . There may be left behind a slight gastric disorder; frequently, also, the scalp remains tender at one spot the following morning . . . For a certain period after the attack I can expose myself with impunity to influences which before would infalli-bly caused an attack.”⁷

This account is of interest showing the remis-sion after an attack; and enophthalmos or miosis, and the red eye, which we would associate with cluster headache. He also deduced both the vascular component of the headache phase, and the role of the sympathetic nerves in inducing vascular constric-tion. Later, in 1873, Edward. Living in his classic text⁸ accepted that dilatation of the arteries might explain the headache, but like Gowers, Living rejected the vascular theory as explanation of the varied content of the aura, its bilaterality in certain patients, and the vegetative symptoms throughout the body, and the changes in patterns of attacks. Living regarded it as a “nerve storm.”

“a form of centrencephalic seizure, the activity of which is projected rostrally upon the cerebral hemispheres, and peripherally via the ramifications of the autonomic nervous system . . .”

In explaining his nerve storm theory⁴ Living considered migraine along with other “neuro-roses” to be:

“a primary and often hereditary disposition of the nervous system itself; this consists in a tendency to the irregular discharge and dilatation of the nerve force . . .”

Time has shown that Living’s and Gowers’ theories are closer to the truth than du Bois Reymond’s, though we still do not understand the initial mechanism.

J M S PEARCE
304 Beverley Road, Anlaby, Hull HU10 7BG, UK
jmspearce@freenet.co.uk

4 Whytt R. Observations on the nature, causes and cure of those disorders commonly called nervous, hypochondriac, or historic. Edinburgh: Becket, Pond, and Balfour, 1764.

www.jnnp.com